Biocon Biologics secures FDA approval for biosimilar bevacizumab

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE: 532523), announced on April 10, 2025, that the U.S. Food and Drug Administration (FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar to Bevacizumab used to treat different types of cancer. Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis, restricting blood supply to the tumor. This approval expands Biocon Biologics' oncology portfolio in the U.S., joining OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe and Canada under the name ABEVMY. The U.S. bevacizumab market recorded sales of approximately USD 2.0 billion in 2023.